rel in-lin quarter drive growth
near-term downgrad share hold
gilead report product revenu in-lin consensu
y/i slightli sequenti non-gaap ep
rel in-lin consensu although non-gaap net incom
declin y/i gilead end quarter cash
less so-so quarter gilead concern
near-term growth prospect therefor lower rate hold
growth come hcv revenu surprisingli continu
erod hiv franchis grow mainli due uptak biktarvi
prep posit substanti enough realli drive signific
growth top-lin know cell therapi still long-term play
addit also must consid potenti headwind around drug price
us head elect cycl
posit outlook partnership galapago glpg nr
although take time revenu perspect assum filgotinib
approv emerg potenti blockbust also could look toward
 activ question would gilead buy could
less immedi accret said long-term prospect could
emerg posit see uncertainti short-term therefor
step hold rate remov price target
commerci updat hcv revenu y/i
sequenti howev partial due statutori claw-back reserv impact
eu revenu hiv franchis continu grow revenu
y/i larg fuel continu biktarvi
growth prescrib regimen hiv well continu growth
prep howev hiv space may becom competit especi
eu truvada gener gilead may nearli satur us market
antivir patient yescarta revenu
sequenti though expect growth mid- long-term
reimburs continu improv new indic ad
revenu guidanc narrow toward top rang manag adjust
revenu guidanc
sg guidanc gross
margin effect tax rate reiter
pressur hiv franchis gilead maintain domin hiv
combin master life-cycl manag world-class
howev wide lead us antiretrovir patient gilead
product us still room signific growth particularli space
becom increasingli competit exampl watch viiv gsk nr
viiv dolutegravir-bas dtg doublet tripl combin
soc hiv product like atripla genvoya biktarvi even quad
pill stribild hold spot among prescrib logic resist
unlik emerg three antivir howev viiv newly-approv dovato
dtg/lamivudin demonstr non-inferior dtg-base triplet week
emerg resist though gilead cite
physician concern resist doublet regimen could limit uptak
biktarvi patient switch dtg regimen drug price
discount could add price pressur
viiv long-act cabenuva anoth potenti threat hiv viiv monthli
inject cabenuva cabotegravir rilpivirin submit nda
approv april found non-inferior drug regimen contain
two nucleosid revers transcriptas inhibitor nrti third agent
compani also report posit data bimonthli version gilead
long-act program capsid inhibitor though earli
expand new market could build long-term prospect loss
blockbust hcv franchis near total market domin hiv
us patient anti-retrovir gilead product gilead period
chang manag search new avenu growth inflammatori
space possibl growth driver filgotinib nda file rheumatoid
arthriti ra japan eu respect gilead also leader car-t
yescarta although revenu modest view see substanti
long-term prospect compani expand await addit data
includ surviv data dlbcl readout earli
steroid intervent cohort data studi
mcl well readout registr studi nhl nash
larg untap potenti market howev failur stellar trial
gilead middl pack next major event atla combin
trial test doublet selonsertib firsocostat cilofexor reading-out later
could help identifi path forward
inflammatori diseas next blockbust space gilead gilead
report posit data three finch trial follow talk
fda manta trial longer delay expect timelin filgotinib
rheumatoid arthriti ra compani file approv eu japan
us expect come nr upadacitinib
alreadi approv howev like approv jak inhibitor olumi
xeljanz carri black box warn showdown upadacitinib
filgotinib expect come balanc safeti efficaci
seek approv low dose upadacitinib possibl due increas
herp zoster infect observ higher dose said filgotinib
demonstr superior humira upadacitinib filgotinib avoid
blackbox may advantag jak view best-in-
class safeti regul may err side caution jakinib class
await clariti regul
model chang reduc revenu estim
high-end guidanc consensu rang combin
adjust lead non-gaap ep addit lower
revenu estim reflect assumpt
modest growth lower non-gaap ep
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
